Coherent Raman Scattering Microscopy in Oncology Pharmacokinetic Research

The high attrition rates of anti-cancer drugs during clinical development remains a bottleneck problem in pharmaceutical industry. This is partially due to the lack of quantitative, selective, and rapid readouts of anti-cancer drug activity in situ with high resolution. Although fluorescence microscopy has been commonly used in oncology pharmacological research, fluorescent labels are often too large in size for small drug molecules, and thus may disturb the function or metabolism of these molecules. Such challenge can be overcome by coherent Raman scattering microscopy, which is capable of chemically selective, highly sensitive, high spatial resolution, and high-speed imaging, without the need of any labeling. Coherent Raman scattering microscopy has tremendously improved the understanding of pharmaceutical materials in the solid state, pharmacokinetics of anti-cancer drugs and nanocarriers in vitro and in vivo. This review focuses on the latest applications of coherent Raman scattering microscopy as a new emerging platform to facilitate oncology pharmacokinetic research.

Automated summary

The high attrition rates of anti-cancer drugs during clinical development pose a challenge in pharmaceutical industry. Fluorescence microscopy, while commonly used in oncology research, may have limitations due to the large size of fluorescent labels. Coherent Raman scattering microscopy offers a promising solution, providing chemically selective, sensitive, high-resolution imaging without the need for labeling, thus facilitating oncology pharmacokinetic research.